Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	268,771	305,137	976,525	1,272,626
Depreciation	347	271	1,041	966
Research and development (including stock-based compensation (Note 8))	135,057	103,529	372,836	387,442
Total operating expenses	404,175	408,937	1,350,402	1,661,034
Loss from operations	(404,175)	(408,937)	(1,350,402)	(1,661,034)
Other expense:
Interest expense	103,084	100,282	363,424	290,082
Total other expense	103,084	100,282	363,424	290,082
Net loss	(507,259)	(509,219)	(1,713,826)	(1,951,116)
Net loss attributable to the noncontrolling interest	516	505	1,789	4,197
Net loss applicable to Bion's common stockholders	$ (506,743)	$ (508,714)	$ (1,712,037)	$ (1,946,919)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.06)	$ (0.07)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	29,640,938	26,842,776	28,633,602	26,291,097